Efficacy and safety of Roxadustat on renal anemia in hemodialysis patients:A meta-analysis

doi:10.3969/j.issn.1004-583X.2022.04.003

Abstract

Abstract:

Objective To compare the efficacy and safety of roxadustat and erythropoietin in the treatment of renal anemia in hemodialysis patients. Methods Randomized controlled studies of roxadustat and erythropoiet regarding renal anemia in hemodialysis patients from PubMed, Web of Science, Embase, Cochrane Library, CNKI, CBM, VIP and WanFang Data were collected by two researchers, the conduction of the database is by February 2021; the extracted literature were evaluated the quality, and Revman 5.4 software was used for meta analysis. Results A total of 540 patients were included in three articles. In the comparison with the control group, the hemoglobin rate could be improved in roxadustat group (OR=2.82, 95%CI 1.06~7.48, P=0.04), and there was no significant difference in the improvement of hemoglobin level between the two groups (MD=-0.13, 95%CI -0.46~0.20, P=0.43). Roxadustat could significantly improve iron-binding capacity, (MD=35.07, 95%CI 12.45-57.70, P=0.002), but the incidence of adverse events was higher in the roxadustat group than that in the control group(OR=1.98, 95%CI 1.30-3.04, P=0.002).Conclusion Roxadustat can effectively reduce renal anemia in hemodialysis patients, but its safety still should be attention widely.

Key words: nephrosis, roxadustat, erythropoietin, hemodialysis, meta analysis

CLC Number:

R692

Zhou Ren, Chen Yating, Zhang Yong. Efficacy and safety of Roxadustat on renal anemia in hemodialysis patients:A meta-analysis[J]. Clinical Focus, 2022, 37(4): 305-310.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2022.04.003

https://huicui.hebmu.edu.cn/EN/Y2022/V37/I4/305

Figures/Tables 11

文献	地点	样本量(例)		年龄( $x -$ ±s,岁)		性别(男/女,例)		研究类型	疗程 (周)	临床试验
文献	地点	T1	T2	T1	T2	T1	T2	研究类型	疗程 (周)	临床试验
Provenzano等2016(1)	美国	41	13	55.8±13.4	59.5±10.1	21/14	9/4	多中心、随机、对照	6	Ⅱ期
Provenzano等2016(2)	美国	67	22	56.9±12.1	57.0±11.6	45/22	14/8	多中心、随机、对照	19	Ⅱ期
Chen等 2017	中国	74	22	50.8±12.6	53.8±10.0	45/29	13/9	多中心、随机、对照	6	Ⅱ期
Akizawa等2020	日本	150	151	64.6±11.7	64.9±10.1	101/49	107/44	多中心、随机、对照、双盲	24	Ⅲ期

文献	地点	样本量(例)		年龄( $x -$ ±s,岁)		性别(男/女,例)		研究类型	疗程 (周)	临床试验
文献	地点	T1	T2	T1	T2	T1	T2	研究类型	疗程 (周)	临床试验
Provenzano等2016(1)	美国	41	13	55.8±13.4	59.5±10.1	21/14	9/4	多中心、随机、对照	6	Ⅱ期
Provenzano等2016(2)	美国	67	22	56.9±12.1	57.0±11.6	45/22	14/8	多中心、随机、对照	19	Ⅱ期
Chen等 2017	中国	74	22	50.8±12.6	53.8±10.0	45/29	13/9	多中心、随机、对照	6	Ⅱ期
Akizawa等2020	日本	150	151	64.6±11.7	64.9±10.1	101/49	107/44	多中心、随机、对照、双盲	24	Ⅲ期

References 14

[1]	Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: Global dimension and perspectives[J]. Lancet, 2013, 382(9888): 260-272. doi: 10.1016/S0140-6736(13)60687-X URL
[2]	Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: A cross-sectional survey[J]. Lancet, 2012, 379(9818): 815-822. doi: 10.1016/S0140-6736(12)60033-6 URL
[3]	肾性贫血诊断与治疗中国专家共识(2018修订版)[J]. 中华肾脏病杂志, 2018, 34(11): 860-866. doi: 10.3760/cma.j.issn.1001-7097.2018.11.012
[4]	Sakaguchi Y, Hamano T, Wada A, et al. Types of erythropoietin-stimulating agents and mortality among patients undergoing hemodialysis[J]. J Am Soc Nephrol, 2019, 30(6): 1037-1048. doi: 10.1681/ASN.2018101007 pmid: 31015255
[5]	白瑞, 张蕾. 低氧诱导因子脯氨酰羟化酶抑制剂治疗肾性贫血的研究进展[J]. 实用医药杂志, 2021, 38(3): 272-276.
[6]	Chen N, Hao C, Liu BC, et al. Roxadustat treatment for Anemia in patients undergoing long-term dialysis[J]. N Engl J Med, 2019, 381(11): 1011-1022. doi: 10.1056/NEJMoa1901713 URL
[7]	李宏彬, 梁军, 马强. 罗沙司他胶囊与重组人促红素治疗肾性贫血的效果及预后比较[J]. 中国医药导报, 2020, 17(8): 178-181.
[8]	王培培, 吴涛. 口服罗沙司他对慢性肾脏病并肾性贫血的治疗效果观察[J]. 山东医药, 2020, 60(33): 73-75.
[9]	Akizawa T, Iwasaki M, Yamaguchi Y, et al. Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan[J]. J Am Soc Nephrol, 2020, 31(7): 1628-1639. doi: 10.1681/ASN.2019060623 pmid: 32493693
[10]	Provenzano R, Besarab A, Wright S, et al. Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: A phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study[J]. Am J Kidney Dis, 2016, 67(6): 912-924. doi: 10.1053/j.ajkd.2015.12.020 pmid: 26846333
[11]	Chen N, Qian J, Chen J, et al. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China[J]. Nephrol Dial Transplant, 2017, 32(8): 1373-1386. doi: 10.1093/ndt/gfx011 URL
[12]	Gupta N, Wish JB. Hypoxia-inducible factor prolyl hydroxylase inhibitors: A potential new treatment for anemia in patients with CKD[J]. Am J Kidney Dis, 2017, 69(6): 815-826. doi: 10.1053/j.ajkd.2016.12.011 URL
[13]	Del Vecchio L, Locatelli F. Roxadustat in the treatment of anaemia in chronic kidney disease[J]. Expert Opin Investig Drugs, 2018, 27(1): 125-133. doi: 10.1080/13543784.2018.1417386 URL
[14]	Zheng Q, Yang H, Sun L, et al. Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: A network meta-analysis[J]. Pharmacol Res, 2020, 159: 105020. doi: 10.1016/j.phrs.2020.105020 URL

[1]	Li Hai, Liu Wenhu, Peng Shaopeng, Wang Fei. Meta-analysis of the efficacy of controlled stepwise decompression versus rapid standard large bone-flap decompression on the treatment of severe craniocerebral injury [J]. Clinical Focus, 2023, 38(9): 788-795.
[2]	Chen Xiaotian, Huo Lijuan. Meta-analysis of clinical significance of serum total bilirubin level in inflammatory bowel disease [J]. Clinical Focus, 2023, 38(8): 677-685.
[3]	Dai Jing, Chen Huaqian. Wunderlich syndrome in a patient on haemodialysis with a review of the literature [J]. Clinical Focus, 2023, 38(12): 1107-1111.
[4]	Sun Yanan, Hao Yifeng, Li Xiaohong. Prevalence of restless legs syndrome in patients with amyotrophic lateral sclerosis and its correlation with disease severity: A meta-analysis [J]. Clinical Focus, 2023, 38(10): 878-882.
[5]	Liu Peihua, Yang Qian, Liu Zhiqiang, Liang Lu. Continuous veno-venous hemodiafiltration plus activated charcoal hemoperfusion in treatment of multiple organ dysfunction syndrome caused by fish bile poisoning: one case [J]. Clinical Focus, 2022, 37(8): 738-742.
[6]	Sun Ying, Yu Qin. Long-term effect of hypoglossal nerve stimulation in the treatment of obstructive sleep apnea hypopnea syndrome: A meta analysis [J]. Clinical Focus, 2022, 37(8): 677-684.
[7]	Yin Yikun, Yin Xunwei, Wang Jialin, Sun Junzhi. Impacts of Tai Chi exercise cycle on blood pressure and cardiovascular risk factors in essential hypertension: a systematic review and meta-analysis [J]. Clinical Focus, 2022, 37(7): 599-606.
[8]	Sun Yanan, Hao Yifeng, Li Xiaohong. Meta analysis on diagnostic value of external anal sphincter electromyography in multiple system atrophy and Parkinson's disease [J]. Clinical Focus, 2022, 37(6): 490-496.
[9]	Guo Ru, Liu Ruihong, Lin Xuefeng, Han Xuanmao, Zhang Zhu, Chen Ruiying. Correlation between cardiac troponin and D-dimer levels and mortality in COVID-19 critical illness patients: A meta analysis [J]. Clinical Focus, 2022, 37(4): 293-298.
[10]	Hu Fangfang, Zhong Shiling, Di Yazhen, Wu Ling. Vascular endothelial function of juvenile idiopathic arthritis in pediatric patients: A systematic review and meta-analysis [J]. Clinical Focus, 2022, 37(3): 204-210.
[11]	Jiang Yan, Li Jiayang, Wu Hongyu, Chen Baolin, Cheng Xiaoming, Lyu Junyuan. MDM4rs4245739 gene polymorphism and breast cancer susceptibility:A meta-analysis [J]. Clinical Focus, 2022, 37(11): 977-984.
[12]	Chen Jie, Chen Shu, Yin Yufeng, Chang Xin, Wu Jian. Computed tomography values of lumbar spine in diagnosing osteoporosis: A meta-analysis [J]. Clinical Focus, 2022, 37(11): 970-976.
[13]	Ma Fei, Fang Xuehua, Gao Dequan, Zhang Wei. Efficacy of Metoprolol Succinate combined with Trimetazidine on coronary heart disease and heart failure: a meta-analysis [J]. Clinical Focus, 2021, 36(6): 491-499.
[14]	Wang Shimeng, Ma Yingji, Wu Ying, Liu Xiaodan, Wang Wei. Effects of HBV infection on liver metastasis of tumor: A meta-analysis [J]. Clinical Focus, 2021, 36(5): 389-394.
[15]	Zhang Jinjin, Jin Ruixia, Sun Wei. High-flux hemodialysis in the frailty of elderly patients with end-stage renal disease [J]. Clinical Focus, 2021, 36(4): 328-331.